ZONGERTINIB
Regimen
- Experimental
- Phase Ia - Dose escalation part
- Control
- Phase Ib - Dose expansion part: Cohort 1
Population
HER2-mutant advanced/metastatic NSCLC, previously treated (phase 1a-1b)
Key finding
Oral HER2-selective TKI in HER2-mutated NSCLC: ORR 71%, mPFS 12.4 mo — FDA accelerated 2025.
Source: PMID 40293180
Timeline
- Enrollment start: 2021-07-02 📎
Guideline citations
- NCCN NSCLC Version 5.2026 (p.4)
- CSCO NSCLC 2025 ⚠️ OCR source